Results 101 to 110 of about 70,621 (279)

Outcomes for Patients With Micro‐Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue, Katrina Moore, Tricia Saurine, David Chan, Lina Pugliano, Connie Diakos   +5 more
wiley   +1 more source

Trastuzumab Increases Risk of Congestive Heart Failure [PDF]

, 2012

openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Correlation between resistance to trastuzumab and miR-141 relative expression in the BT-474 human breast cancer cell line

مجله دانشگاه علوم پزشکی بیرجند, 2017
Background and Aim: Resistance to trastuzumab has been a critical barrier to targeted therapy of HER 2-positive (Human Epidermal Growth Factor Receptor 2) breast cancers.
Zohreh Rezaei, Dor Mohammad Kordi-Tamandani, Ahmadreza Sebzari, Kazem Dastjerdi   +3 more
doaj  

Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2‐Expressing Breast Cancers

ChemistryOpen, 2019
The preparation and in vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)‐chelated 89Zr have been reported.
Dr. Joo Hee Jang, Sang Jin Han, Dr. Jung Young Kim, Dr. Kwang Il Kim, Dr. Kyo Chul Lee, Dr. Chi Soo Kang   +5 more
doaj   +1 more source

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis [PDF]

, 2016
Laura Pizzuti, Isabella Sperduti, Andrea Michelotti, Claudia Omarini, Teresa Gamucci, Clara Natoli, Loretta D’Onofrio, Francesco Giotta, Corrado Ficorella, Lucio Laudadio, Alessandra Cassano, Paolo Marchetti, Vincenzo Adamo, M. Mauri, A.F. Scinto, G. Zampa, Agnese Fabbri, Lucia Mentuccia, Sandro Barni, Patrizia Vici   +19 more
openalex   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2‐Positive Cancers

Cancer Science, EarlyView.
Overexpression of ABC transporters, especially ABCG2 and ABCB1, mediates acquired resistance to T‐DXd in HER2‐positive cancers. Inhibition of these transporters restored T‐DXd efficacy, highlighting efflux‐mediated resistance as a potential therapeutic target. ABSTRACT Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer
Yuya Murase, Shigeki Nanjo, Sachiko Arai, Sota Kondo, Hayato Koba, Yifeng Liu, Koji Fukuda, Shigeki Sato, Jun Kinoshita, Noriyuki Inaki, Tsukasa Ueda, Shunichi Nomura, Yuichi Tambo, Takahiro Shimizu, Masafumi Horie, Daichi Maeda, Richard W. Wong, Kazuyoshi Hosomichi, Takafumi Kobayashi, Satoshi Watanabe, Kenta Yamamura, Noriyuki Ohkura, Miki Abo, Seiji Yano   +23 more
wiley   +1 more source

Complete Regression of Ductal Carcinoma in Situ Following Chemotherapy and Trastuzumab: Should we Rethink Management? [PDF]

, 2015
Robert O. Dillman
openalex   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

Cancer Science, EarlyView.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda, Takayoshi Watanabe, Toshinori Ozaki, Yasuhiko Kamikubo   +3 more
wiley   +1 more source